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Obesity and undernutrition are common in South Africa and affect 
the health of people living with the human immunodeficiency 
virus (PLHIV).1-3 Weight gain and changes in other anthropometric 
markers, including body shape, are common among those on 
antiretroviral therapy (ART); some who are underweight become 
obese on therapy.4
Excessive weight gain is a risk factor for chronic non-communicable 
diseases including diabetes, hypertension, cardiovascular disease and 
dyslipidaemia.4,5 Central obesity is a stronger predictor of metabolic 
syndrome than body mass index (BMI).6 Obesity is also a risk factor 
for the development of lactic acidosis, a potentially life-threatening 
adverse effect of ART. Lipodystrophy is a complication of ART 
that presents as truncal obesity, enlarged breasts and peripheral 
wasting of the buttocks, limbs and face.7-9 Factors that influence 
anthropometric perception and behaviour of PLHIV regarding their 
weight include culture, socio-economic status, education and the 
stigma surrounding HIV infection.10,11
PLHIV lose lean mass with disease progression, which further 
impairs their immune system and increases their predisposition to 
opportunistic infections and mortality risk.2
A cohort study design is a useful way to track changes in BMI, waist 
circumference (WC) and waist:hip ratio (WHR). Internationally, 
significant increases in anthropometric markers in PLHIV have been 
reported; however, larger samples are required to validate South 
African study findings.4,7,12
BMI and waist and hip circumference measurements are simple, 
quick to perform, reliable (after training in the technique) and 
suitable for evaluating nutritional status of subjects in resource 
constrained settings. Their utility is enhanced if done together 
with dietary history, plasma albumin, haemoglobin levels and bio-
impedance analyses. Monitoring trends is of more value than single 
measurements.13
An analysis of more than 600 PLHIV on ART in the USA that 
compared WC and WHR and used magnetic resonance imaging to 
assess adipose tissue deposits, found a strong association with increases 
in these anthropometric markers and indicators of metabolic risk 
(p<0.001). The researchers concluded that, despite HIV-associated 
lipodystrophy, measuring WC and WHR remains a highly effective 
nutritional screening tool in resource constrained settings.13
Monitoring of anthropometric markers in PLHIV initiating ART 
potentially enables earlier recognition of lipodystrophy, timeous 
lifestyle counselling and, if necessary, adjustment of drug regimens.9 
Many lipodystrophy body changes are not reversible, underscoring 
the importance of a baseline measurement to facilitate earlier 
detection.7
Dietary counselling and promoting a healthy lifestyle can reduce 
the risk of developing obesity and chronic non-communicable 
diseases.14 Patients who are undernourished require dietary 
counselling, supplementation and close monitoring to detect 
opportunistic infections.2,3
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Background. Obesity and undernutrition are common in South 
Africa and influence the health outcomes of people living with the 
human immunodeficiency virus (PLHIV).
Aim. To describe the anthropometric changes and perceptions 
of body weight in adults initiated on antiretroviral therapy (ART).
Methods. A cohort of 230 PLHIV was enrolled at an HIV clinic in 
Durban. Changes in their body mass index, and waist and hip girth 
were measured 6-monthly in the 12 months following initiation of 
ART. Data on demographic and socio-economic variables, CD4 
counts, opportunistic infections and drug regimens used were 
recorded. Perceptions of body weight and desire to change these 
were ascertained.
Results. Weight perceptions of respondents were incongruent 
with their body mass index, with the trend being to judge 
themselves as weighing less than their actual weight. Those wanting 
to gain weight gained an average of 7.8 kg – 2.8 times more than 
those satisfied with their weight (p<0.001). After 12 months on 
ART, there was a statistically significant increase in anthropometric 
measurements (p<0.001) with 43 of the 110 women having waist 
circumferences that increased their risk of cardiovascular disease; 
the incidence of lipodystrophy was 35% (62/177) (95% confidence 
interval 27 - 42%), 36% (64/177) were overweight and 22% (39/177) 
were obese, compared with 21% (49/230) and 12% (28/230) 
respectively at baseline (p=0.002).
Conclusion. There is a strong association between PLHIV’s 
perception of body weight, their desire to gain weight and their 
actual weight gain on ART. Lipodystrophy, weight gain and truncal 
obesity are common among PLHIV after initiating ART.
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We studied the evolution of anthropometric markers and 
perceptions of body weight in adults living with HIV in the first 12 
months after initiating ART at an HIV clinic in Durban to determine 
predictors of these changes in order to improve nutritional and 
healthy lifestyle promotion. Since weight perceptions are likely to 
influence weight gain, we studied patients’ body weight perceptions 
and their aspiration to gain or lose weight, and compared these with 
their actual anthropometric changes.
Methods
We used an observational, descriptive cohort study design, and 
enrolled 230 consecutive HIV-positive outpatients initiating ART 
between June and October 2009 and followed them up for 12 months 
at the Sinikithemba HIV Clinic at McCord Hospital in Durban. 
This is a state-aided, semi-private, urban hospital where patients 
pay R140 (US$20) monthly for comprehensive HIV care, including 
psychosocial support to improve adherence and nutritional advice 
to promote a healthy lifestyle. ART-naïve adults between the ages 
of 18 and 50 years commencing ART were included. Pregnant 
women and those unable to speak isiZulu or English were excluded. 
Approaching all eligible patients for recruitment during the study 
period minimised selection bias. Only 5 declined.
Height, weight, and waist and hip measurements were measured 
at baseline and the latter three again at 6 and 12 months. Baseline 
demographic data and health status variables including CD4 count, 
haemoglobin level, co-morbid illnesses, opportunistic infections 
including tuberculosis, and drug regimens used were obtained from 
medical records. Drug substitutions, inter-current opportunistic 
infections, CD4 counts and viral load were recorded at 6 and 12 
months. A questionnaire, administered by a trained isiZulu-speaking 
research assistant, was used to collect data on income, education 
level, number of dependants and the respondents’ perceptions 
of body weight, desire to change this, and reasons for wanting 
to change. Information bias was reduced by in-depth training 
and weekly supervision of field workers by the hospital dietician. 
Measurement bias was reduced by using calibrated instruments and 
standard anthropometric techniques.
Height was measured using a wall-mounted stadiometer. Subjects 
were weighed without shoes and in minimal clothing, with a 
calibrated electronic scale to the nearest 0.1 kg. Waist and hip 
circumference were measured to the nearest 0.1 cm using a flexible, 
non-elastic tape measure (Seca) with the patient standing upright 
with feet together and arms at their sides. Waist measurement was 
measured at the mid-point between the lowest rib and the iliac 
crest, and hip circumference as the maximal circumference over the 
buttocks. Both were performed twice and their mean was calculated.
BMI was calculated in kg/m2 and categorised as underweight 
(BMI <18.5), normal (18.5≤BMI< 25), overweight (25≤BMI<30), 
and obese (BMI≥30). WHR was calculated as the ratio of the waist 
girth to the hip girth. Lipodystrophy was diagnosed with a WHR 
>0.95 in males and >0.85 in females or if other characteristic changes 
associated with lipodystrophy, including truncal obesity, enlarged 
breasts, buffalo hump and peripheral wasting in the buttocks, limbs 
and face, were reported. A WC ≥88 cm in women and ≥102 cm in 
men identified those at increased risk of cardiovascular disease. 
Active tuberculosis (TB) was recorded if TB had been diagnosed 
within the 3 months before initiating ART or during the 12-month 
study period.
Data were analysed using SPSS version 15.0 (SPSS Inc., Chicago). 
Baseline characteristics were compared between males and females 
using non-parametric Mann-Whitney tests in the case of continuous 
non-normally distributed or ordinal variables and Pearson’s chi-
square tests for categorical variables. Associations between predictor 
variables including time and the anthropometric change were 
assessed using population averaged generalised estimating equation 
(GEE) models to account for some missing data at 6 and 12 months’ 
follow-up. Age, gender and other socio-economic variables and the 
presence of TB were controlled for in the analyses by using them 
as covariates or factors in the models. Exchangeable correlation 
matrices were specified. One-way analysis of variance (ANOVA) 
tests compared mean weight change over 12 months with the 
respondents’ desire to gain weight, lose weight or remain the same.
The University of KwaZulu-Natal Biomedical Research Ethics 
Committee (BF 154/08) and McCord Hospital provided ethical 
approval for the study. Written informed consent was obtained from 
participants.
Results
Baseline cohort characteristics
The cohort comprised 230 black PLHIV commencing ART, of 
whom 144 (63%) were female; their median age was 35 years (inter-
quartile range (IQR) 29 - 39). TB was diagnosed in 90 (39%) in the 
3 months before initiating ART and in a further 30 (13%) in the 12 
months thereafter. The median baseline CD4 count was 97 cells/
mm3 (IQR 44 - 169); 65 (28%) patients had a CD4 count <50 cells/
mm3. Twenty-three (10%) patients were underweight (BMI <18). All 
participants were initiated on standard stavudine- and lamivudine-
containing regimens with 206 (90%) on efavirenz and 24 (10%) on 
nevirapine as the third drug (Table I).
Of the 230 enrolled patients, 210 (91%) had 2 sets of measurements 
recorded, and 177 (77%) had anthropometry at all 3 time points 
(Fig. 1); 28 (12%) changed their service provider, 12 (5.2%) were 
lost to follow-up, 11 (4.8%) died, and there was one pregnancy and 
one defaulter. One hundred and thirty-one (74%) gained weight, 
and those who were underweight at baseline (13/15, 87%) had the 
highest proportional increase (Table II).
The mean baseline BMI was 21.9 kg/m2 for males and 25.0 kg/
m2 for females. BMI increased significantly over time with a mean 
increase of 2.4 kg/m2 (95% CI 1.7 - 3.1) between baseline and 
12 months in males (p<0.001) and 2.2 kg/m2 (95% CI 1.5 - 2.9) 
in females (p<0.001) (Table III). Increase in BMI was positively 
associated with age (p=0.001) and negatively associated with current 
TB in females (p=0.018) (Table IV). After one year on ART, 64 (36%) 
of the remaining cohort (177) were overweight and 39 (22%) were 
obese compared with 49 (21%) and 28 (12%) respectively at baseline 
(p=0.002).
The mean baseline weight was 63.6 kg for males and 63.5 kg for 
females. Weight increased significantly over time (p<0.001) with 
a mean adjusted increase of 6.8 kg in males and 5.6 kg in females 
between baseline and 12 months (Table III). Increase in weight in 
these females was positively associated with the age of the study 
participant (p=0.008) and negatively associated with them currently 
having TB. Females who started ART with TB and those who 
developed TB during the study period both gained significantly less 
weight in 12 months (6.2 kg less, p=0.021 and 6.5 kg less, p=0.015 
respectively) compared with those who did not have TB, after 
controlling for age, education level and income bracket (Table IV).
Among patients who wished to gain weight, 83% (94/113) 
achieved this with a mean increase of 7.8 kg. Of those who wanted 
to stay the same weight, 60.7% (34/56) gained, with a mean weight 
gain of 2.7 kg (Table V).
The mean baseline WC was 77.3 cm for males and 77.2 cm for 
females. WC increased significantly over time, with a mean increase 
of 7.2 cm in males and 7.8 cm in females between baseline and 
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Table I. Baseline characteristics of PLHIV in the anthropometric study at McCord Hospital, 2009 (N=230)
Male Female
n (%) n (%) p-value
Number of patients 86 (37.4%) 144 (62.6%)
Median age in years (IQR) 36.0 (31.0 - 41.0) 33.5 (28.0 - 38.5) 0.026
Employment
   Employed 48 (55.8%) 74 (51.4%) 0.515
   Income <R2 000 (US$290) 39 (45.3%) 90 (62.5%) 0.011
   Number of dependants 5.5 (4 - 7) 5 (4 - 7) 0.077
Education
   Tertiary/technical 21 (24.4%) 46 (31.9%)
   Secondary 48 (55.8%) 79 (54.9%)
   None or primary 17 (19.8%) 19 (13.2%) 0.281
Opportunistic infections
   Active TB in 3 months prior to ART 43 (50%) 47 (32.6%)
   Active TB after ART initiation 7 (8.1%) 23 (16%) 0.021
   Chronic diarrhoea 8 (9.3%) 9 (6.3%)
   Cryptococcal meningitis 3 (3.5%) 3 (2.1%)
   Pneumocystis jirovecci 1 (1.2%) 4 (2.8%)
   Other 4 (4.7%) 5 (3.5%) 0.731
ART regimen
   Stavudine/lamivudine/efavirenz 78 (90.7%) 128 (88.9%)
   Savudine/lamivudine/nevirapine 8 (9.3%) 16 (11.1%) 0.664
   Drug substitution by 6 months 4 (4.7%) 14 (9.7%)
   Drug substitution by 12 months 12 (14%) 40 (27.8%) 0.941
Laboratory results
   Median haemoglobin (IQR) 11.4 (10 - 13) 10.6 (9.3 - 12) 0.001
   Median CD4 (IQR) 82.5 (27 - 162) 99.5 (52 - 170.5) 0.175
12 months (p<0.001) (Table III). Increase in WC was positively 
associated with age in women (p=0.003) and men (p=0.006) (Table 
IV). There was a significantly higher proportion of women (39.1%, 
43/110) with WC >88.0 cm compared with men, in whom 5 (7.5%, 
5/67) had a WC >102.0 cm after 12 months of ART (p<0.001).
The mean baseline hip circumference was 87.4 cm for males and 
96.9 cm for females. Hip circumference increased significantly, with 
a mean increase of 7.7 cm in males and 6.9 cm in females between 
baseline and 12 months of ART (p<0.001) (Table III). Increase in 
Table II. Change in weight over 12 months according to 
baseline BMI
Weight change category
BMI baseline category Increased Decreased
Underweight 13 (86.7%) 2 (13.3%)
Normal 81 (81.8%) 18 (18.2%)
Overweight 26 (65%) 14 (35%)
Obese 11 (45.8%) 13 (54.2%)
   Total 131 (73.6%) 47 (26.4%)
p=0.001.
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Fig. I. Flow diagram of HIV-infected anthropometric study patients on ART in Durban 
followed up from 2009 - 2010. 
CSP=changed service provider; LTFU=lost to follow-up; Defaulted=stopped 
treatment. 
 
N=230 (100%) 
Baseline measurement 
N=210/230 (91.3%) 
Two measurements 
N=177/230 (76.96%) 
Three measurements 
CSP 17/230 (7.4%) 
LTFU 12/230 (5.2%) 
Deaths 2/230 (0.1%) 
Pregnant 1/230 (0.04%) 
Defaulted 1/230 (0.04%) 
CSP 11/230 (4.7%) 
Deaths 9/230 (3.9%) 
Fig. I. Flow diagram of HIV-infected anthropometric study patients on ART 
in Durban followed up from 2009 - 2010 (CSP = changed service provider; 
LTFU = lost to follow-up; Defaulted = stopped treatment).
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hip circumference in females was positively associated with their 
age (p=0.017) and negatively associated with having TB (p=0.04) 
(Table IV).
The mean baseline WHR was 0.89 in males and 0.80 in females 
(Table III). Overall, 62 (35%, 95% CI 28 - 42%) of the participants 
developed lipodystrophy within 12 months of commencing ART. 
Of these, 50 participants (81%) were diagnosed according to 
WHR measurements and 12 (19%) were according to self-reported 
symptoms. Nine (15%) of the 62 who developed lipodystrophy 
according to their WHR were not diagnosed by the attending 
clinician or reported by the participant. There was a significant 
increase in WHR of 0.086 (95% CI 0.065 - 0.107) in males and 
0.082 (95% CI 0.065 - 0.1) in females who developed lipodystrophy 
(p<0.001) (Table IV).
Participants’ baseline perceptions of body 
weight
At baseline, 93 (40%) of all participants felt that they were 
underweight, 117 (51%) said that they were ‘just right’, and 15 (6.5%) 
that they were overweight.
Baseline weight perceptions were compared with actual baseline 
BMI categories and, of those who were underweight, 74% (17/23) 
assessed themselves correctly. In those with a normal BMI, 46% 
(59/128) assessed themselves as being underweight, and 53% 
(68/128) felt that they were just right. In the overweight BMI 
category, 61% (30/49) felt that they were just right and 25% (12/49) 
assessed themselves as being underweight. Among obese patients, 
26% (7/27) felt that they were overweight, 19% (5/27) that they were 
underweight, and 48% (13/27) that they were just right. Therefore, 
respondents’ perceptions of their weight were not congruent with 
reality, the trend being to judge themselves as being less than their 
actual weight, which was not objectively accurate (Table VI).
Regarding their desire to change their current weight status, 152 
(66%) (N=230 at baseline) wanted to gain weight, 9 (3.9%) to lose 
weight, and 69 (30%) to remain the same. Correlating desire to gain 
weight with actual baseline BMI, only 13% were underweight, 64% 
were in the normal BMI category, 18% were overweight, and 5% 
were obese. Among those wanting to remain the same weight, 48% 
were in the normal BMI category, 28% were overweight and 22% 
were obese.
The main reasons given for desiring to change weight included 
wanting to return to their ‘normal weight’ (55%), to be ‘healthy’ 
(45%), problems with ill-fitting clothing or finances related to 
purchasing new clothes (29%), stigma surrounding HIV (24%), and 
feeling unhealthy (8.7%).
Discussion
Our findings build on studies of anthropometric evolution in PLHIV 
on ART in South Africa and on studies of patients’ perceptions of 
their weight and how these influence weight gain.7,15 We aimed to 
describe anthropometric change in a larger South African cohort of 
PLHIV along with their  perceptions regarding body weight.
Consistent with other studies, weight, BMI, and waist and hip 
circumference increased significantly in all PLHIV commencing 
ART, although WHR only increased significantly in patients with 
lipodystrophy.4,7,15
There is a high incidence of lipodystrophy among PLHIV on 
stavudine-containing regimens (35% after a year of ART), as 
measured by a WHR >0.95 in males and >0.85 in females or by their 
report of symptoms. Lipodystrophy caused by stavudine should 
be actively screened for to identify and manage this adverse effect. 
Baseline and repeated waist and hip circumference measurement 
can facilitate its identification. Metabolic changes accompanying 
lipodystrophy increase the risk for cardiovascular disease in 
PLHIV on ART, an important consideration in their long-term 
management.7,9
PLHIV wishing to gain weight significantly increased their weight, 
underscoring the importance of eliciting their desire to gain weight 
Table III. Anthropometric changes in adults living with HIV during the first year of antiretroviral therapy at McCord  
Hospital, 2009/10
Baseline 6 months 1 year
GEE coefficient* for 
mean changes (95% CI) p- values*
Females N=144 N=132 N=110
Weight (mean) (95% CI) 63.5 (61.0 - 66.0) 68.3 (65.7 - 71.0) 69.8 (66.9 - 72.6) 5.6 (3.8 - 7.3) <0.001
BMI (mean) (95% CI) 25.0 (24.1 - 25.8) 26.8 (26.0 - 27.7) 27.4 (26.4 - 28.4) 2.2 (1.5 - 2.9) <0.001
Waist circumference (mean) (95% CI) 77.2 (75.4 - 79.0) 81.2 (79.2 - 83.1) 85.5 (83.4 - 87.6 ) 7.8 (6.2 - 9.3) <0.001
Hip circumference (mean) (95% CI) 96.9 (95.1 - 98.7) 102.7 (100.7 - 104.8) 104.5 (102.1 - 106.8) 6.9 (5.0 - 8.8) <0.001
Waist:hip ratio (mean) (95% CI) 0.8 (0.79 - 0.81) 0.79 (0.78 - 0.80) 0.82 (0.81 - 0.83) 0.02 (0.009 - 0.035) 0.001†
Males N=86 N=78 N=67
Weight (mean) (95% CI) 63.6 (61.5 - 65.7) 68.4 (65.9 - 70.8) 71.3 (68.4 - 74.2) 6.8 (4.9 - 8.7) <0.001
BMI (mean) (95% CI) 21.9 (21.2 - 22.6) 23.6 (22.7 - 24.5) 24.6 (23.6 - 25.6) 2.4 (1.7 - 3.1) <0.001
Waist circumference (mean) (95% CI) 77.3 (75.7 - 79.0) 81.9 (79.9 - 84.0) 85.2 (82.8 - 87.6) 7.2 (5.6 - 8.9) <0.001
Hip circumference (mean) (95% CI) 87.4 (85.9 - 88.9) 94.1 (92.3 - 95.9) 95.7 (93.9 - 97.4) 7.7 (6.0 - 9.4) <0.001
Waist:hip ratio (mean) (95% CI) 0.89 (0.88 - 0.90) 0.87 (0.86 - 0.88) 0.89 (0.88 - 0.90) 0.004 (-0.008 - 0.016) 0.489†
*Coefficients and p-values are for the effect of time on the change in outcome between baseline and 12 months.
†p-values and coefficients adjusted for TB , age, income, education and lipodystrophy.
p-values and coefficients adjusted using GEE models for TB , age, income, and education.
Dependent variables are weight, BMI, WHR and waist and hip circumferences. Independent variables are time, TB, age, income and education.
649September 2011, Vol. 101, No. 9  SAMJ
Table IV. Population-based generalised estim
ating equations for BM
I, weight, waist circum
ference, hip circum
ference and waist:hip ratio for PLH
IV
 in the anthropom
etric study, M
cC
ord H
ospital, 2009
                 BM
I
         W
eight
      W
aist circum
ference
            H
ip circum
ference
              W
aist:hip ratio
Independent variables
C
oefficient (CI)
p-value
C
oefficient (CI)
p-value
C
oefficient (CI)
p-value
C
oefficient (CI)
p-value
C
oefficient (CI)
p-value
Fem
ales
(Intercept)
18.31 (11.84 - 24.78)
<0.001
46.60 (27.22 - 65.97)
<0.001
64.24 (50.32 - 78.16)
<0.001
86.21 (71.4 - 101.02)
<0.001
0.709 (0.655 - 0.764)
<0.001
Tim
e at 12 m
onths
2.19 (1.50 - 2.88)
<0.001
5.56 (3.78 - 7.34)
<0.001
7.75 (6.19 - 9.31)
<0.001
6.90 (5.01 - 8.79)
<0.001
0.022 (0.009 - 0.035)
0.001
Tim
e at 6 m
onths
1.57 (1.13 - 2.00)
<0.001
3.96 (2.82 - 5.10)
<0.001
3.58 (2.28 - 4.88)
<0.001
5.20 (3.95 - 6.46)
<0.001
-0.007 (-0.02 - 0.006)
0.307
Tim
e at baseline
0*
0*
0*
0*
0*
TB in 3 m
onths prior to A
RT
-1.81 (-3.6 - –0.03)
0.046
-6.2 (-11.48 - –0.92)
0.021
-2.67 (-6.33 - 1.0)
0.154
-5.33 (-9.46 - –1.20)
0.011
0.029 (0.011 - 0.048)
0.001
TB after starting A
RT
-2.4 (-4.39 - –0.40)
0.018
-6.5 (-11.74 - –1.26)
0.015
-4.82 (-8.85 - –0.78) 
0.019
-4.86 (-9.51 - –0.22)
0.04
0.003 (-0.023 - 0.029)
0.83
N
o TB
0*
0*
0*
0*
0*
.
A
ge
0.2 (0.08 - 0.32)
0.001
0.49 (0.13 - 0.86)
0.008
0.4 (0.14 - 0.65)
0.003
0.35 (0.06 - 0.63)
0.017
0.001 (0.00 - 0.002)
0.028
Incom
e
0.35 (-0.09 - 0.79)
0.117
0.70 (-0.47 - 1.88)
0.241
0.35 (-0.67 - 1.37)
0.503
0.73 (-0.17 - 1.62)
0.111
0.002 (-0.006 - 0.002)
0.363
Education
-0.02 (-0.81 - 0.77)
0.969
0.28 (-2.01 - 2.58)
0.808
0.05 (-1.62 - 1.71)
0.957
-0.11 ( -1.85 - 1.64)
0.902
0.003 (-0.004 - 0.010)
0.408
Lipodystrophy at 12 m
onths
0.082 (0.065 - 0.100)
<0.001
Lipodystrophy at baseline
0*
Scale
26.07
217.18
119.09
 
144.14
0.003
M
ales
(Intercept)
18.74 (12.71 - 24.76)
<0.001
59.1 (40.70 - 77.5)
<0.001
60.5 (45.78 - 75.22)
<0.001
80.87 (69.16 - 92.58)
<0.001
0.778 (0.704 - 0.852)
<0.001
Tim
e at 12 m
onths
2.38 (1.71 - 3.06)
<0.001
6.76 (4.85 - 8.68)
<0.001
7.25 (5.58 - 8.92)
<0.001
7.67 (5.97 - 9.38)
<0.001
0.004 (-0.008 - 0.016)
0.489
Tim
e at 6 m
onths
1.50 (0.97 - 2.03)
<0.001
4.13 (2.63 - 5.62)
<0.001
4.14 (2.76 - 5.53)
<0.001
6.18 (4.77 - 7.58)
<0.001
-0.015 (-0.025 - –0.005)
0.003
Tim
e at baseline
0*
0*
0*
0*
0*
TB in 3 m
onths prior to A
RT
-1.18 (-2.7 - 0.34)
0.127
-1.72 (-6.33 - 2.90)
0.466
-2.09 (-5.76 - 1.59)
0.266
-1.37 (-4.3 - 1.56)
0.359
-0.014 (-0.031 - 0.003)
0.096
TB after starting A
RT
-0.5 (-2.81 - 1.82)
0.674
0.35 (-7.13 - 7.83)
0.927
1.20 (-5.90 - 8.31)
0.74
0.90 (-4.94 - 6.74)
0.763
-0.001 (-0.022 - 0.019)
0.912
N
o TB
0*
0*
0*
0*
0*
A
ge
0.10 (-0.02 - 0.22)
0.092
0.077 (-0.29 - 0.44)
0.677
0.42 (0.12 - 0.71)
0.006
0.12 (-0.13 - 0.36)
0.351
0.03 (0.001 - 0.004)
<0.001
Incom
e
0.17 (-0.14 - 0.48)
0.283
0.73 (-0.25 - 1.7)
0.145
0.23 (-0.61 - 1.07)
0.597
0.34 (-0.32 - 1.0)
0.318
0.001 (-0.002 - 0.005)
0.404
Education
-0.09 (-0.62 - 0.43) 
0.729
0.05 (-1.73 - 1.82)
0.960
0.44 (-0.81 - 1.68)
0.493
0.42 (-0.73 - 1.57)
0.477
-0.003 (-0.010 - 0.004)
0.437
Lipodystrophy at 12 m
onths
0.086 (0.065 - 0.107)
<0.001
Lipodystrophy at baseline
0*
(Scale)
12.22
 
116.11
 
77.4
 
55.04
 
0.002
 
*Set to zero because this param
eter is redundant.
D
ependent variables are w
eight, BM
I, W
H
R and w
aist and hip circum
ferences. Independent variables are tim
e, TB, age, incom
e and education.
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and the reasons for this, when counselling about dietary and lifestyle 
modification; stigma remains an underlying reason for this.11 The 
significant proportion of patients who became overweight or obese 
is a concern as PLHIV on ART are at increased risk for developing a 
range of chronic non-communicable diseases.5,15
There is a mismatch between the baseline BMI and PLHIVs 
perception of whether their weight was ‘normal’. The reasons include 
cultural norms regarding ideal body size and stigma surrounding 
HIV, in which weight loss is an important external marker of the 
disease. Appropriate counselling is needed to address perceptions 
among PLHIV about their weight and health so as to counteract 
any misperceptions, since these appear to influence whether or not 
patients will gain weight.10,11,15
Potential confounding factors, including TB, age, socio-economic 
status and education levels of participants, were controlled for in 
the GEE analyses. Possible limitations to the study are that McCord 
Hospital is a semi-private hospital that may serve a different socio-
economic group to PLHIV obtaining ART from Department of 
Health clinics, which could compromise the generalisability of the 
data. Intensive training and close supervision of the 3 enrolled 
nurses who conducted the anthropometry should have reduced the 
inter-observer bias.
More research is needed into effective counselling methods to 
understand and address  perceptions regarding weight that are 
applicable in the existing local cultural context. The stigma that 
surrounds HIV and incorrect concepts of ‘health’ and what is 
considered ‘normal’ weight remain driving factors in the desire that 
PLHIV have to gain weight. Educational campaigns and community 
involvement must be mobilised to bring about change in this area.
The need for a greater emphasis on lifestyle and dietary counselling 
for PLHIV on ART, by providers (including counsellors, nurses and 
doctors) is highlighted. Lipodystrophy (as an adverse drug effect of 
stavudine) has a high incidence and must be actively screened for, 
although this should become less of a problem in the future, with 
the new national ART guidelines recommending a change from  d4T 
to TDF. Baseline and sequential waist and hip measurements are 
strongly recommended for all PLHIV initiating ART.
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Table VI. Gender-specific baseline weight perceptions by actual baseline BMI category
         Actual BMI category (column %)
Patients’ baseline weight perception (N (%))   Underweight         Normal             Overweight           Obese
Females (N=144)
   Underweight     11 (91.7%)             39 (54.9%)   10 (30.3%)            5 (17.9%)
   Right      1 (8.3%)             30 (42.3%)   19 (57.6%)            13 (46.4%)
   Other      0 (0%)             2 (2.8%)   4 (12.1%)              10 (35.7%)
      Total      12 (100%)             71 (100%)   33 (100%)             28 (100%)
Males (N=86)
   Underweight     6 (54.5%)             20 (33.9%)   2 (12.5%)               0 (0%)
   Right      5 (45.5%)             38 (64.4%)   11 (68.8%)            0 (0%)
   Other      0 (0%)             1 (1.7%)   3 (18.7%)              0 (0%)
      Total      11 (100%)             59 (100%)   16 (100%)             0 (0%)
Table V. Mean change in weight between baseline and 12 
months by participants’ desire to change weight
Gender
Patients’ 
desire to 
change 
weight
Mean 
change in 
weight (kg) N 95% CI p-value
Male Gain 7.2 45 (5.2 - 9.2)
Lose -40.59 1
Same 4.1 21 (0.6 - 7.7)
Total 6.8 67 (4.8 - 8.8) <0.001
Female Gain 8.2 68 (5.9 - 10.5)
Lose -4.6 8 ( -10.9 - 0.9)
Same 1.8 35 (-1.1 - 4.7)
Total 5.3 111 (3.4 - 7.1) <0.001
Total Gain 7.8 113 (6.2 - 9.4)
Lose 0.5 9 (-10.5 - 11.4)
Same 2.7 56 (0.5 - 4.9)
Total 5.8 178 (4.4 - 7.2) 0.001
